Literature DB >> 17524981

Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases.

Amir Masoud Sadaghiani1, Steven H L Verhelst, Vasilena Gocheva, Kimberly Hill, Eva Majerova, Sherman Stinson, Johanna A Joyce, Matthew Bogyo.   

Abstract

The papain-family cathepsins are cysteine proteases that are emerging as promising therapeutic targets for a number of human disease conditions ranging from osteoporosis to cancer. Relatively few selective inhibitors for this family exist, and the in vivo selectivity of most existing compounds is unclear. We present here the synthesis of focused libraries of epoxysuccinyl-based inhibitors and their screening in crude tissue extracts. We identified a number of potent inhibitors that display selectivity for endogenous cathepsin targets both in vitro and in vivo. Importantly, the selectivity patterns observed in crude extracts were generally retained in vivo, as assessed by active-site labeling of tissues from treated animals. Overall, this study identifies several important compound classes and highlights the use of activity-based probes to assess pharmacodynamic properties of small-molecule inhibitors in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17524981     DOI: 10.1016/j.chembiol.2007.03.010

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  23 in total

1.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Authors:  Benelita Tina Elie; Vasilena Gocheva; Tanaya Shree; Stacie A Dalrymple; Leslie J Holsinger; Johanna A Joyce
Journal:  Biochimie       Date:  2010-05-04       Impact factor: 4.079

2.  Abundance- and Activity-Based Proteomics in Platelet Biology.

Authors:  Stephen P Holly; Xian Chen; Leslie V Parise
Journal:  Curr Proteomics       Date:  2011-10       Impact factor: 0.837

3.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

Review 4.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

5.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

6.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 7.  New approaches for dissecting protease functions to improve probe development and drug discovery.

Authors:  Edgar Deu; Martijn Verdoes; Matthew Bogyo
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

8.  Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment.

Authors:  Georgy Mikhaylov; Ursa Mikac; Anna A Magaeva; Volya I Itin; Evgeniy P Naiden; Ivan Psakhye; Liane Babes; Thomas Reinheckel; Christoph Peters; Robert Zeiser; Matthew Bogyo; Vito Turk; Sergey G Psakhye; Boris Turk; Olga Vasiljeva
Journal:  Nat Nanotechnol       Date:  2011-08-07       Impact factor: 39.213

Review 9.  Application of activity-based probes to the study of enzymes involved in cancer progression.

Authors:  Margot G Paulick; Matthew Bogyo
Journal:  Curr Opin Genet Dev       Date:  2008-02-21       Impact factor: 5.578

10.  Cysteine Cathepsin Inhibitors as Anti-Ebola Agents.

Authors:  Wouter A van der Linden; Christopher J Schulze; Andrew S Herbert; Tyler B Krause; Ariel A Wirchnianski; John M Dye; Kartik Chandran; Matthew Bogyo
Journal:  ACS Infect Dis       Date:  2016-01-20       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.